SMARCA1 and neoplasm: Using the same strategies of targeting mutant SWI/SNF, the HDAC6 inhibitor ACY1215 combined with anti-PD-L1 antibody reduced tumour burden and eliminated ascites in an in vivo model of ARID1A-inactivated OCCC [160].